Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Gross Profit: 2022-2025

Historic Gross Profit for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to $159.1 million.

  • Axsome Therapeutics' Gross Profit rose 65.15% to $159.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $515.6 million, marking a year-over-year increase of 67.25%. This contributed to the annual value of $352.4 million for FY2024, which is 44.11% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Gross Profit stood at $159.1 million, which was up 16.46% from $136.6 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Gross Profit registered a high of $159.1 million during Q3 2025, and its lowest value of $14.9 million during Q3 2022.
  • In the last 3 years, Axsome Therapeutics' Gross Profit had a median value of $87.0 million in 2023 and averaged $91.3 million.
  • In the last 5 years, Axsome Therapeutics' Gross Profit soared by 243.53% in 2023 and then fell by 21.05% in 2024.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Gross Profit stood at $22.1 million in 2022, then skyrocketed by 190.54% to $64.2 million in 2023, then soared by 68.74% to $108.3 million in 2024, then surged by 65.15% to $159.1 million in 2025.
  • Its Gross Profit was $159.1 million in Q3 2025, compared to $136.6 million in Q2 2025 and $111.7 million in Q1 2025.